Interní Med. 2006; 8(7): 314-322

Combination therapy of dyslipidemia

prof. MUDr. Jan Bultas CSc

II. interní klinika kardiologie a angiologie 1. LF UK a VFN, Praha

Dyslipidemia is a multifactorial disease participating in etiopathogenesis of cardiovascular diseases. The treatment targeted on lipid spectrum adjustment belongs together with antihypertensive medications, to the most effective, but also the most expensive treatment options improving prognosis of patients. Because of various combinations of abnormalities in lipid spectrum and a narrow therapeutic spectrum of individual hypolipidemics it is frequently necessary to combine individual hypolipidemics. In the review different combinations suitable for a decrease of LDL-cholesterol (statins+ezetimib, statins+resins), decrease of LDL- cholesterol and triglycerides and simultaneous increase of HDL-cholesterol (stating-niacin, statin-fibrates, ezetimib+ fibrates) or potentiation of HDL-cholesterol increase (niacin+fibráty) are discussed. Individual approaches as far as its contribution, risks and effectiveness are discussed. A part of this article is also a review of further development.

Keywords: Key words: combination therapy of dyslipidemia, hypolipidemics, statins, ezetimib, niacin, fibrates, torcetrapib, cardiovascular prevention.

Published: June 1, 2006  Show citation